FDA Clears Exoskeleton for Spinal Cord Injury - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Clears Exoskeleton for Spinal Cord Injury

Use is limited to level indoor and adjoining outdoor areas and requires supervision by a companion with specialized training.

  • By

  • Kathryn Wighton

  • August 12, 2026

  • 2 min

Share

Clinical Scorecard: FDA Clears Exoskeleton for Spinal Cord Injury

At a Glance

CategoryDetail
ConditionSpinal Cord Injury
Key MechanismsSelf-balancing technology for mobility assistance
Target PopulationEligible adults with spinal cord injury who can operate the device
Care SettingClinical trial and personal use with trained companions

Key Highlights

  • Eve allows wheelchair users with spinal cord injury to walk without using hands
  • Device cleared based on clinical trial assessing safety and function
  • Participants reported improvements in health status and psychological well-being
  • Training enabled users to perform daily living activities
  • Commercial availability planned for September 17, 2026

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Individuals with spinal cord injury, approximately 308,620 in the US

          Device training and oversight by a trained companion are essential for use

          Clinical Best Practices

          • Structured training for device operation
          • Assessment of function and usability in daily settings
          • Monitoring user-reported outcomes for health and well-being

          Related Resources & Content

          Original Source(s)

          FDA Clears Exoskeleton for Spinal Cord Injury

          • by Kathryn Wighton

          • August 12, 2026

          Related Content

          The Loan Cap That Could Shrink the Doctor Pipeline

          New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

          Serial Bias Differs in Schizophrenia vs Bipolar Disorder

          Findings suggest a schizophrenia-like subgroup within bipolar disorder, with implications for targeted treatment approaches

          Misdiagnosis Common in Parkinsonian Disorders

          Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.